4th March 2014: Sphere Fluidics Featured in Nature Biopharma Dealmakers
Sphere Fluidics has been profiled in the March edition of Nature Biopharma Dealmakers. The article was entitled "Using picodroplets to find the next blockbuster" and was authored by Dr Rob Marchmont (Commercial Director of Sphere Fluidics). The article discusses company commercial and technical progress over the last year and the ability of picodroplets to perform upto one billion assays per biochip per day. More information can be found here: viewer.zmags.com/publication/a8f9d17d#/a8f9d17d/16.
28th February 2014: Sphere Fluidics' Picodroplet Technology Appears on TED Video on Synthetic Biology.
Sphere Fluidics' picodroplet technology was discussed in a TED video discussing how synthetic biology is exploring biological complexity. The speaker was Dr Sean Ward (a co-Founder and Chief Technology Officer of Synthace - a leading UK company focussing on Synthetic Biology). The video can be seen here: https://www.youtube.com/watch?v=1G8dQQrlbbA.
21st February 2014: Sphere Fluidics to Attend BioEurope Spring 2014.
Dr Frank F. Craig (CEO) and Dr Marian Rehak (R&D Director) will be attending BioEurope 2014 in Turin (Italy) during March 10th -12th. "We will also be exhibiting at the UK Pavilion and look forward to meeting other industry executives at the biopartnering event" said Dr Craig. "I am looking forward to discussing our new exciting instrumentation development program with other companies. Sphere Fluidics is planning to develop the world's first integrated Monoclonality Assurance System. Monoclonality is essential for biopharmaceutical approval by all major, regulatory agencies. Our device provides significant operational cost-savings as well as up to 100-fold improvement in statistical accuracy" said Dr Rehak. Conference information can be found here: www.ebdgroup.com/bes/index.php.